论文部分内容阅读
目的:探讨恩替卡韦联合聚乙二醇干扰素抗乙肝病毒的疗效。方法:乙肝抗病毒治疗患者72例随机分为试验组和对照组,每组36例。试验组给予恩替卡韦联合聚乙二醇干扰素抗病毒治疗;对照组单独给予恩替卡韦治疗。分别比较治疗24,48周,以及停药后6个月时两组患者的HBe Ag转换率、HBe Ag阴转率、HBV-DNA阴转率、HBs Ag清除率、AST和ALT复常率等指标,以及治疗期间两组的药品不良反应。结果:治疗24周时,两组患者各项指标比较,差异均无统计学意义(P>0.05);治疗48周和停药6个月时,试验组患者各项指标均明显高于对照组(P<0.05)。两组药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:聚乙二醇干扰素联合恩替卡韦抗乙肝病毒治疗临床疗效明显优于单用恩替卡韦,且安全性较好,值得临床推广。
Objective: To investigate the efficacy of entecavir combined with pegylated interferon against hepatitis B virus. Methods: A total of 72 patients with hepatitis B virus antiviral therapy were randomly divided into experimental group and control group, 36 cases in each group. The experimental group was treated with entecavir combined with peginterferon and the control group was given entecavir alone. The HBe Ag conversion rate, HBeAg negative conversion rate, HBV-DNA negative conversion rate, HBsAg clearance rate, AST and ALT normalization rate, etc. were compared between the two groups after treatment for 24,48 weeks and 6 months after stopping treatment Indicators, and adverse drug reactions in both groups during treatment. Results: After treatment for 24 weeks, there was no significant difference between the two groups (P> 0.05). After treatment for 48 weeks and withdrawal for 6 months, the indexes in the experimental group were significantly higher than those in the control group (P <0.05). There was no significant difference between the two groups in the incidence of adverse drug reactions (P> 0.05). Conclusion: The clinical efficacy of pegylated interferon combined with entecavir against hepatitis B virus is better than that of entecavir alone, and it is safe and worthy of clinical promotion.